JP2016539625A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539625A5 JP2016539625A5 JP2016521355A JP2016521355A JP2016539625A5 JP 2016539625 A5 JP2016539625 A5 JP 2016539625A5 JP 2016521355 A JP2016521355 A JP 2016521355A JP 2016521355 A JP2016521355 A JP 2016521355A JP 2016539625 A5 JP2016539625 A5 JP 2016539625A5
- Authority
- JP
- Japan
- Prior art keywords
- maf
- amplification
- copy number
- expression level
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 104
- 230000014509 gene expression Effects 0.000 claims description 101
- 210000000988 bone and bone Anatomy 0.000 claims description 64
- 239000000523 sample Substances 0.000 claims description 60
- 206010027476 Metastases Diseases 0.000 claims description 54
- 102100039189 Transcription factor Maf Human genes 0.000 claims description 54
- 230000009401 metastasis Effects 0.000 claims description 54
- 101150095688 maf gene Proteins 0.000 claims description 51
- 230000003321 amplification Effects 0.000 claims description 46
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 46
- 206010006187 Breast cancer Diseases 0.000 claims description 37
- 208000026310 Breast neoplasm Diseases 0.000 claims description 37
- 108010089507 Proto-Oncogene Proteins c-maf Proteins 0.000 claims description 34
- 102000007987 Proto-Oncogene Proteins c-maf Human genes 0.000 claims description 34
- 239000003112 inhibitor Substances 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 30
- 238000000338 in vitro Methods 0.000 claims description 28
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 27
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 27
- 102000014128 RANK Ligand Human genes 0.000 claims description 24
- 108010025832 RANK Ligand Proteins 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 230000015556 catabolic process Effects 0.000 claims description 18
- 238000006731 degradation reaction Methods 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 230000002265 prevention Effects 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 206010027452 Metastases to bone Diseases 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 230000005945 translocation Effects 0.000 claims description 9
- 229940122361 Bisphosphonate Drugs 0.000 claims description 8
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 8
- 208000003076 Osteolysis Diseases 0.000 claims description 8
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 8
- 150000004663 bisphosphonates Chemical class 0.000 claims description 8
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 claims description 7
- 229960005562 radium-223 Drugs 0.000 claims description 7
- 108020004635 Complementary DNA Proteins 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 6
- 102000001332 SRC Human genes 0.000 claims description 6
- 238000010804 cDNA synthesis Methods 0.000 claims description 6
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 229940125436 dual inhibitor Drugs 0.000 claims description 6
- 229940043355 kinase inhibitor Drugs 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 6
- 108010087686 src-Family Kinases Proteins 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 102000053642 Catalytic RNA Human genes 0.000 claims description 5
- 108090000994 Catalytic RNA Proteins 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 5
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 5
- 230000000010 osteolytic effect Effects 0.000 claims description 5
- 108091092562 ribozyme Proteins 0.000 claims description 5
- 102000055006 Calcitonin Human genes 0.000 claims description 4
- 108060001064 Calcitonin Proteins 0.000 claims description 4
- 230000004544 DNA amplification Effects 0.000 claims description 4
- 102000008108 Osteoprotegerin Human genes 0.000 claims description 4
- 108010035042 Osteoprotegerin Proteins 0.000 claims description 4
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 4
- 229960004015 calcitonin Drugs 0.000 claims description 4
- 230000002759 chromosomal effect Effects 0.000 claims description 4
- 229940111134 coxibs Drugs 0.000 claims description 4
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 4
- 229960001251 denosumab Drugs 0.000 claims description 4
- 230000009977 dual effect Effects 0.000 claims description 4
- 239000002834 estrogen receptor modulator Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims description 4
- 238000003752 polymerase chain reaction Methods 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 229940079488 strontium ranelate Drugs 0.000 claims description 4
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 claims description 4
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical group OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 4
- 229960004276 zoledronic acid Drugs 0.000 claims description 4
- 150000004922 Dasatinib derivatives Chemical group 0.000 claims description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 3
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 claims description 3
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 3
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims description 3
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 102100036899 Parathyroid hormone-related protein Human genes 0.000 claims description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 3
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 3
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 3
- 229960001292 cabozantinib Drugs 0.000 claims description 3
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical group C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 229960002448 dasatinib Drugs 0.000 claims description 3
- 229960005167 everolimus Drugs 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 102000004171 Cathepsin K Human genes 0.000 claims description 2
- 108090000625 Cathepsin K Proteins 0.000 claims description 2
- 229940122156 Cathepsin K inhibitor Drugs 0.000 claims description 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 2
- 229940097000 DKK-1 inhibitor Drugs 0.000 claims description 2
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims description 2
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 claims description 2
- QHLITPHIARVDJI-UHFFFAOYSA-N [1-[4-(2-naphthalenyl)-2-pyrimidinyl]-4-piperidinyl]methanamine Chemical compound C1CC(CN)CCN1C1=NC=CC(C=2C=C3C=CC=CC3=CC=2)=N1 QHLITPHIARVDJI-UHFFFAOYSA-N 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000003498 protein array Methods 0.000 claims description 2
- 238000011002 quantification Methods 0.000 claims description 2
- 238000003753 real-time PCR Methods 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102100036893 Parathyroid hormone Human genes 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 101150097381 Mtor gene Proteins 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000011337 individualized treatment Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- RWRDJVNMSZYMDV-SIUYXFDKSA-L (223)RaCl2 Chemical compound Cl[223Ra]Cl RWRDJVNMSZYMDV-SIUYXFDKSA-L 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 101001068638 Homo sapiens Basic salivary proline-rich protein 3 Proteins 0.000 description 1
- 101000879840 Homo sapiens Serglycin Proteins 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940092814 radium (223ra) dichloride Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361888984P | 2013-10-09 | 2013-10-09 | |
| US61/888,984 | 2013-10-09 | ||
| PCT/IB2014/002675 WO2015052583A2 (en) | 2013-10-09 | 2014-10-07 | Method for the prognosis and treatment of cancer metastasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539625A JP2016539625A (ja) | 2016-12-22 |
| JP2016539625A5 true JP2016539625A5 (OSRAM) | 2017-11-24 |
| JP6550045B2 JP6550045B2 (ja) | 2019-07-24 |
Family
ID=52292968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521355A Active JP6550045B2 (ja) | 2013-10-09 | 2014-10-07 | 乳がんに由来する骨の転移がんの予後診断および処置のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170101683A1 (OSRAM) |
| EP (2) | EP3055429B1 (OSRAM) |
| JP (1) | JP6550045B2 (OSRAM) |
| KR (1) | KR20160061424A (OSRAM) |
| CN (1) | CN105980576B (OSRAM) |
| AU (1) | AU2014333513B2 (OSRAM) |
| BR (1) | BR112016007864A2 (OSRAM) |
| CA (1) | CA2926894A1 (OSRAM) |
| DK (1) | DK3055429T3 (OSRAM) |
| ES (1) | ES2727904T3 (OSRAM) |
| MX (2) | MX362041B (OSRAM) |
| TR (1) | TR201907389T4 (OSRAM) |
| WO (1) | WO2015052583A2 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3091085B1 (en) | 2010-10-06 | 2019-02-27 | Institució Catalana de Recerca I Estudis Avançats | Method of designing a therapy for breast cancer metastasis |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| US20140105918A1 (en) | 2012-10-12 | 2014-04-17 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| WO2014140896A2 (es) | 2013-03-15 | 2014-09-18 | Fundacio Privada Institut De Recerca Biomedica | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer |
| CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| DK3458610T3 (da) * | 2016-05-25 | 2021-06-07 | Inbiomotion Sl | Terapeutisk behandling af brystcancer baseret på c-MAF-status |
| CN105907886A (zh) * | 2016-07-07 | 2016-08-31 | 蔡维泺 | miR-124在乳腺癌骨转移疾病中的应用 |
| AU2018372762B2 (en) * | 2017-11-22 | 2025-08-21 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| WO2019232283A1 (en) | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| RU2757960C1 (ru) * | 2021-01-11 | 2021-10-25 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") | Способ прогнозирования статуса рецептора эпидермального фактора роста her2/neu в метастатических лимфатических узлах у больных раком молочной железы |
| RU2766248C1 (ru) * | 2021-01-11 | 2022-02-10 | Федеральное государственное бюджетное научное учреждение "Томский национальной исследовательский медицинский центр Российской академии наук ("Томский НИМЦ") | Способ прогнозирования статуса рецептора эпидермального фактора роста her2/neu в первичной опухоли у больных раком молочной железы |
| CN113667748B (zh) * | 2021-07-19 | 2023-07-25 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | circIKBKB的抑制剂及其检测试剂在乳腺癌骨转移诊断、治疗和预后试剂盒的应用 |
| CN114512183B (zh) * | 2022-01-27 | 2022-09-20 | 北京吉因加医学检验实验室有限公司 | 一种预测met基因扩增或多倍体的方法及装置 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3688418T2 (de) | 1985-02-13 | 1993-08-26 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| EP0910652B1 (en) | 1996-04-05 | 2014-10-08 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| DE951551T1 (de) | 1996-12-23 | 2000-09-14 | Immunex Corp., Seattle | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| US6982475B1 (en) | 1998-03-20 | 2006-01-03 | Mcsp, Llc | Hermetic wafer scale integrated circuit structure |
| HK1039108A1 (zh) | 1999-03-15 | 2002-04-12 | Axys Pharmaceuticals, Inc. | 以n-氰甲基酰胺作为蛋白酶抑制剂 |
| TW404030B (en) | 1999-04-12 | 2000-09-01 | Siliconware Precision Industries Co Ltd | Dual-chip semiconductor package device having malposition and the manufacture method thereof |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| JP2003525874A (ja) | 2000-01-06 | 2003-09-02 | メルク フロスト カナダ アンド カンパニー | プロテアーゼ阻害剤としての新規化合物および組成物 |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| DK2270052T3 (en) | 2001-06-26 | 2018-07-02 | Amgen Inc | Antibodies to OPGL |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| AU2003903540A0 (en) | 2003-07-09 | 2003-07-24 | Atdec Pty Ltd | Flat panel display wall mounting system |
| WO2005026322A2 (en) | 2003-09-11 | 2005-03-24 | Clontech Laboratories, Inc. | siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME |
| WO2005029067A2 (en) * | 2003-09-24 | 2005-03-31 | Oncotherapy Science, Inc. | Method of diagnosing breast cancer |
| WO2005046731A1 (en) | 2003-10-17 | 2005-05-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| WO2005060722A2 (en) | 2003-12-18 | 2005-07-07 | President And Fellows Of Hardvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| WO2006012221A2 (en) | 2004-06-25 | 2006-02-02 | The Regents Of The University Of California | Target cell-specific short interfering rna and methods of use thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| CA2632451C (en) | 2005-12-06 | 2015-11-03 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| EP1961825A1 (en) * | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| MX2009012650A (es) | 2007-05-24 | 2010-02-18 | Ablynx Nv | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. |
| WO2009114534A1 (en) | 2008-03-14 | 2009-09-17 | The Regents Of The University Of California | Multi-gene classifiers and prognostic indicators for cancers |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| EP2435071A1 (en) * | 2009-05-29 | 2012-04-04 | F. Hoffmann-La Roche AG | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| WO2011017687A1 (en) | 2009-08-06 | 2011-02-10 | Ray Partha S | Diagnosis of primary and metastatic basal-like breast cancer and other cancer types |
| EP3091085B1 (en) * | 2010-10-06 | 2019-02-27 | Institució Catalana de Recerca I Estudis Avançats | Method of designing a therapy for breast cancer metastasis |
| US9066963B2 (en) * | 2011-03-15 | 2015-06-30 | The University Of North Carolina At Chapel Hill | Methods of treating breast cancer with anthracycline therapy |
| EP2650682A1 (en) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
-
2014
- 2014-10-07 MX MX2016004557A patent/MX362041B/es active IP Right Grant
- 2014-10-07 BR BR112016007864A patent/BR112016007864A2/pt not_active Application Discontinuation
- 2014-10-07 DK DK14824529.3T patent/DK3055429T3/en active
- 2014-10-07 EP EP14824529.3A patent/EP3055429B1/en active Active
- 2014-10-07 JP JP2016521355A patent/JP6550045B2/ja active Active
- 2014-10-07 WO PCT/IB2014/002675 patent/WO2015052583A2/en not_active Ceased
- 2014-10-07 CA CA2926894A patent/CA2926894A1/en not_active Abandoned
- 2014-10-07 ES ES14824529T patent/ES2727904T3/es active Active
- 2014-10-07 AU AU2014333513A patent/AU2014333513B2/en active Active
- 2014-10-07 TR TR2019/07389T patent/TR201907389T4/tr unknown
- 2014-10-07 EP EP19165007.6A patent/EP3524698A1/en not_active Withdrawn
- 2014-10-07 CN CN201480064111.7A patent/CN105980576B/zh active Active
- 2014-10-07 KR KR1020167011949A patent/KR20160061424A/ko not_active Withdrawn
- 2014-10-07 US US15/027,946 patent/US20170101683A1/en not_active Abandoned
-
2016
- 2016-04-08 MX MX2019000091A patent/MX2019000091A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539625A5 (OSRAM) | ||
| JP2016516403A5 (OSRAM) | ||
| Du et al. | Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism | |
| JP2016105731A5 (OSRAM) | ||
| JP2018078911A5 (OSRAM) | ||
| Pavlovic et al. | Enhanced MAF oncogene expression and breast cancer bone metastasis | |
| CN104797935B (zh) | 用于癌症转移的预后和治疗的方法 | |
| López‐Knowles et al. | PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality | |
| Ocana et al. | Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis | |
| Banin Hirata et al. | Molecular markers for breast cancer: prediction on tumor behavior | |
| Zucali et al. | Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin | |
| JP2015521050A5 (OSRAM) | ||
| Kim et al. | S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy | |
| WO2013182912A4 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
| Sponziello et al. | PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells | |
| EP2669682A1 (en) | Novel prognostic and predictive biomarkers (tumor markers) for human breast cancer | |
| CN106661624B (zh) | 用于癌症诊断、预后和治疗选择的着丝粒/动粒蛋白基因 | |
| Dovey et al. | Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies | |
| CN105980576A (zh) | 用于源自乳腺癌的骨转移癌的预后和治疗的方法 | |
| EP2307886A2 (en) | Signatures and determinants associated with metastasis and methods of use thereof | |
| CN105324491A (zh) | 用于癌症转移的诊断和治疗的方法 | |
| Kim et al. | Strong correlation of indoleamine 2, 3-dioxygenase 1 expression with basal-like phenotype and increased lymphocytic infiltration in triple-negative breast cancer | |
| JP2019523641A5 (OSRAM) | ||
| JP6603474B2 (ja) | 癌治療 | |
| CA2970469A1 (en) | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |